Literature DB >> 10899430

Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism.

S Gandy1, S Petanceska.   

Abstract

Alzheimer's disease (AD) is characterized by the intracranial accumulation of the 4 kDa amyloid-beta peptide (Abeta), following proteolysis of a approximately 700-amino acid, integral membrane precursor, the Alzheimer amyloid precursor protein (APP). The best evidence causally linking APP to AD has been provided by the discovery of mutations within the APP coding sequence that segregate with disease phenotypes in autosomal dominant forms of familial AD (FAD). Though FAD is rare ( < 10% of all AD), the hallmark features (amyloid plaques, neurofibrillary tangles, synaptic and neuronal loss, neurotransmitter deficits and dementia) are indistinguishable when FAD is compared with typical, common, 'non-familial', or sporadic, AD (SAD). Studies of some clinically relevant mutant APP molecules from FAD families have yielded evidence that APP mutations can lead to the enhanced generation or aggregability of Abeta, consistent with a pathogenic role in AD. Other genetic loci for FAD have been discovered which are distinct from the immediate regulatory and coding regions of the APP gene, indicating that defects in molecules other than APP can also specify cerebral amyloidogenesis and FAD. To date, all APP and non-APP FAD mutations can be demonstrated to have the common feature of promoting amyloidogenesis of Abeta. Epidemiological studies indicate that postmenopausal women on estrogen replacement therapy (ERT) have their relative risk of developing SAD diminished by about one third as compared with age-matched women not receiving ERT [M.X. Tang, D. Jacobs, Y. Stern, K. Marder, P. Schofield, B. Gurland, H. Andrews, R. Mayeux, Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet 348 (2000) 429432]. Because of the key role of cerebral Abeta accumulation in initiating AD pathology, it is most attractive that estradiol might modulate SAD risk or age-at-onset by inhibiting Abeta accumulation. A possible mechanistic basis for such a scenario is reviewed here.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899430     DOI: 10.1016/s0925-4439(00)00031-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  A review of imaging agent development.

Authors:  Eric D Agdeppa; Mary E Spilker
Journal:  AAPS J       Date:  2009-05-05       Impact factor: 4.009

Review 2.  Platelets and Alzheimer's disease: Potential of APP as a biomarker.

Authors:  Geneviève Evin; Qiao-Xin Li
Journal:  World J Psychiatry       Date:  2012-12-22

3.  EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.

Authors:  Jamie Winderbaum Fernandez; Kavon Rezai-Zadeh; Demian Obregon; Jun Tan
Journal:  FEBS Lett       Date:  2010-09-17       Impact factor: 4.124

4.  blue cheese mutations define a novel, conserved gene involved in progressive neural degeneration.

Authors:  Kim D Finley; Philip T Edeen; Robert C Cumming; Michelle D Mardahl-Dumesnil; Barbara J Taylor; Maria H Rodriguez; Calvin E Hwang; Michael Benedetti; Michael McKeown
Journal:  J Neurosci       Date:  2003-02-15       Impact factor: 6.167

Review 5.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease.

Authors:  Sara E Dodson; Olav M Andersen; Vinit Karmali; Jason J Fritz; Dongmei Cheng; Junmin Peng; Allan I Levey; Thomas E Willnow; James J Lah
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

7.  Ovarian steroids regulate gene expression related to DNA repair and neurodegenerative diseases in serotonin neurons of macaques.

Authors:  C L Bethea; A P Reddy
Journal:  Mol Psychiatry       Date:  2015-01-20       Impact factor: 15.992

8.  Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol.

Authors:  Suzana S Petanceska; Steven DeRosa; Ali Sharma; Nichole Diaz; Karen Duff; Steven G Tint; Lorenzo M Refolo; Miguel Pappolla
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.